Novocastra Ready-to-Use Mouse Monoclonal Antibody Terminal Deoxynuceotidyl Transferase Staining Reagent; an in vitro staining reagent for the qualitative identification by light microscopy of Terminal Deoxynucleotidyl Transferase molecules in paraffin sections; Catalog No. RTU-TdT-339; packaged in 7 mL vials; Leica Biosystems Newcastle Ltd., Balliol Business Park West, Benton Lane, Newcastle Upon Tyne NE12 8EW, United Kingdom. RTU-TdT-339 is intended for the qualitative identification by light microscopy of Terminal Deoxynucleotidyl Transferase molecules in paraffin sections. The clinical interpretation of any staining or its absence should be complemented by morphological studies using proper controls and should be evaluated within the context of the patient's clinical history and other diagnostic tests by a qualified pathologist.
Publicado el 19 de diciembre de 2012 · Inicio del retiro: 14 de noviembre de 2012
Resumen
FDA registra el retiro Z-0521-2013 de dispositivos médicos de Clase II, publicado el 19 de diciembre de 2012 e iniciado el 14 de noviembre de 2012. Empresa responsable: Leica Microsystems, Inc.; Estado: Finalizado; Cantidad reportada: 322 vials; Lote: Catalog No. RTU-TdT-339, lot numbers 6001845, expiry 2012-11 and 6009645, expiry 2014-04 The recall also included the folowing expired lots: 804804, 804805, 804806, 804809, 804810, 804812. La Clase II indica posibles consecuencias temporales o médicamente reversibles, o una probabilidad remota de consecuencias graves.
Estado reportado al momento de publicación: Terminated — openFDA actualiza semanalmente y este campo no refleja el estado más reciente. Confirma siempre con la fuente oficial.
Qué peligro representa
RTU-TdT-339 is not stable up to the expiry date on the product labeling, affecting the staining intensity.
Qué hacer
Voluntary: Firm initiated · Letter
Recibe un correo cuando FDA publique un retiro como este
Gratis. Solo te escribimos cuando hay un retiro nuevo que coincide. Te das de baja con un clic.
Detalles del retiro
- Fabricante
- Leica Microsystems, Inc.
- Distribuidor
- Worldwide Distribution -- USA including Arkansas, California, Florida, Illinois, Maryland, Michigan, Minnesota, Missouri, North Carolina, Oregon, Rhode Island, Tennessee, Texas and Wisconsin, and the country of Canada.
- Lote
- Catalog No. RTU-TdT-339, lot numbers 6001845, expiry 2012-11 and 6009645, expiry 2014-04 The recall also included the folowing expired lots: 804804, 804805, 804806, 804809, 804810, 804812
- Clasificación de riesgo
- Class II
- Área (FDA)
- device
- País
- United States
Retiros relacionados
- FDABOND Ready-To-Use Primary Antibody CDX2 (EP25), REF PA037522 de septiembre de 2021
- FDABOND Polymer Refine Detection Kit, Catalog No. DS9800. This detection system is for in vitro diagnostic use.18 de diciembre de 2019
- FDALeica M530 OHX Microscope System Supplied with 100 - 120 Vac.15 de agosto de 2018
- FDANussloch GmbH ASP6025 Tissue Processor12 de julio de 2017
- FDASTERRAD CYCLESURE 24 Biological Indicator (BI) product, P/N 14324. Validation kits with Sterrad Cyclesure 2419 de diciembre de 2012
- FDACobas b 123 POC system cobas b 123 POC system is fully automated POC system for whole blood in vitro19 de diciembre de 2012
Preguntas sobre este retiro
¿Novocastra Ready-to-Use Mouse Monoclonal Antibody Terminal Deoxynuceotidyl Transferase Staining Reagent; an in vitro staining reagent for the qualitative identification by light microscopy of Terminal Deoxynucleotidyl Transferase molecules in paraffin sections; Catalog No. RTU-TdT-339; packaged in 7 mL vials; Leica Biosystems Newcastle Ltd., Balliol Business Park West, Benton Lane, Newcastle Upon Tyne NE12 8EW, United Kingdom. RTU-TdT-339 is intended for the qualitative identification by light microscopy of Terminal Deoxynucleotidyl Transferase molecules in paraffin sections. The clinical interpretation of any staining or its absence should be complemented by morphological studies using proper controls and should be evaluated within the context of the patient's clinical history and other diagnostic tests by a qualified pathologist. fue retirado del mercado?
Sí. FDA publicó el retiro Z-0521-2013 el 19 de diciembre de 2012. Peligro reportado: RTU-TdT-339 is not stable up to the expiry date on the product labeling, affecting the staining intensity.
¿Qué debo hacer si tengo este producto?
Voluntary: Firm initiated · Letter